NRAS and melanoma: Somatic mutations in genes encoding protein actors of this phosphorylation cascade constitutively activate the MAPK pathway: mutations in BRAF, neurofibromin 1 (NF1), NRAS, and c-KIT are the most frequent, representing 50, 20, 20, and 2% of melanomas, respectively [3].